Articles

Prostate Cancer: Highlights from 2006 eulogo1

By: Pierre Mongiat-Artus

European Urology, Volume 6 Issue 1, July 2007, Pages 728-736

Published online: 01 July 2007

Keywords: Bone mineral density, Brachytherapy, Chemotherapy, High-intensity focused ultrasound (HIFU), Hormone therapy, Prostate cancer, PSA, PSADT, Prostatectomy, Zoledronic acid

Abstract Full Text Full Text PDF (658 KB)

Abstract

Objectives

This review provides an overview of the most relevant findings on prostate cancer (PCa) presented at the 2006 annual meetings of the European Association of Urology, American Urological Association, and the American Society of Clinical Oncology, which were discussed during the “New Horizons in Urology” closed meeting in Marbella, Spain, in October 2006.

Methods

Experts in the field of PCa selected and discussed the most relevant new studies. In addition, the participants’ opinion on two representative case studies was assessed by interactive voting, and results were commented on by the PCa experts.

Results

With regard to the early detection of PCa, it was shown that there is no real PSA threshold. In addition, studies on active surveillance indicated that this is a feasible strategy for carefully selected patients, but that those patients with a PSA doubling time <12 mo are at elevated risk for PCa-associated progression and death. Furthermore, it was demonstrated that, besides histopathologic data of radical prostatectomy (RP) specimens, Partin tables also are not 100% reliable. Regarding localised disease, interim analysis at 67-mo follow-up showed that radiation therapy is comparable to RP in terms of survival and disease progression. High-intensity focused ultrasound is associated with low morbidity. Finally, intermittent hormonal therapy for advanced disease might be an option for regular practice. Zoledronic acid was found to prevent bone complications in patients on androgen-deprivation therapy.

Conclusion

Relevant new data on PCa presented at the major 2006 urologic/oncologic meetings have potential to improve screening, detection, and management of this disease.

Take Home Message

This paper communicates recent data on prostate cancer (PCa) screening and detection, and on new findings with regard to the different treatment modalities of local and advanced PCa.

Keywords: Bone mineral density, Brachytherapy, Chemotherapy, High-intensity focused ultrasound (HIFU), Hormone therapy, Prostate cancer, PSA, PSADT, Prostatectomy, Zoledronic acid.

Footnotes

Hôpital St Louis, 1, Avenue Claude Vellefaux, 75010 Paris, France

lowast Tel. +33 1 42494949; Fax: +33 1 42499616.

z.star Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.

Place a comment

Your comment *

max length: 5000